IBD
-
A long-acting anti-TL1A mAb with best-in-class potential
If you are interested in this product, please contact us at BD@drugtimes.cn, we will send the non-confidential deck to you for review
-
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
If you are looking for a promising TL1A product, please contact DrugTimes BD Team (BD@drugtimes.cn)
-
TOP10 MNC Seeking FIC or BIC Products: Inflammatory bowel disease (IBD)
Project ID: BP-20240430-L-EE-81 About IBD Inflammatory bowel disease (IBD) is a gro…